Have Questions?

Global Headquarters

Tel: +44 (0)20 7377 0800
Fax: +44 (0)20 7349 5157

North America

Tel: 1-617-573-9450
Fax: 1-617-573-9542

Japan

Tel: +81 (0)80-1164-4754

Request a Demo

What our customers are saying

When I think of the future, I think of EvaluatePharma

Senior Director,
Global pharmaceutical company

EvaluatePharma World Preview 2017, Outlook to 2022

Pricing pressure causes worldwide drug sales forecasts to fall for first time in 10 years

EvaluatePharma World Preview 2017 EvaluatePharma World Preview 2017 EvaluatePharma World Preview 2017

Download Report

The new edition of our annual report, EvaluatePharma World Preview 2017, Outlook to 2022 discusses the impact that increased scrutiny around the pricing of medicines is starting to have on drug sales growth.

Despite consensus forecasts for worldwide drug sales hitting $1.06trn in 2022, this is down from the $1.12trn analysts forecast for the same period last year. The fall also represents the first time in 10 years of Evaluate analysis that total drug sales have failed to beat previous year forecasts.

This report brings together many of our analyses to provide a top level insight, from the world's financial markets, into the expected performance of the industry between now and 2022.

Highlights


  • Worldwide prescription drug sales forecasted to grow at a robust 6.5% (CAGR) through 2022 to reach $1.06trn
  • 32% of the 2022 increase in sales to come from orphan drugs (+$95bn)
  • Sales at risk worth $194bn potentially signal a second patent cliff era with the advent of biosimilars     

View Report Executive Summary

Press Release


Confirm your details on form below to download this report